Immuneering (NASDAQ:IMRX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Immuneering (NASDAQ:IMRX) from a sell rating to a hold rating in a research note released on Saturday.

Several other research analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a research report on Tuesday, September 30th. Leerink Partnrs raised shares of Immuneering to a “strong-buy” rating in a report on Friday, October 31st. Needham & Company LLC increased their price target on shares of Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immuneering in a research report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Immuneering Stock Performance

Shares of IMRX stock opened at $6.35 on Friday. The company has a market capitalization of $263.97 million, a price-to-earnings ratio of -3.57 and a beta of 0.46. Immuneering has a 52-week low of $1.10 and a 52-week high of $10.08. The company has a 50-day simple moving average of $6.86 and a two-hundred day simple moving average of $4.41.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). On average, sell-side analysts forecast that Immuneering will post -1.86 EPS for the current fiscal year.

Insider Buying and Selling at Immuneering

In other Immuneering news, Director Peter Feinberg purchased 7,500 shares of the stock in a transaction dated Friday, October 3rd. The shares were bought at an average price of $6.67 per share, with a total value of $50,025.00. Following the completion of the transaction, the director directly owned 156,766 shares in the company, valued at approximately $1,045,629.22. This trade represents a 5.02% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 20,800 shares of company stock valued at $143,754 in the last three months. 22.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immuneering

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Flower City Capital purchased a new position in Immuneering during the second quarter valued at approximately $108,000. HighTower Advisors LLC boosted its holdings in Immuneering by 17.7% in the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock valued at $128,000 after purchasing an additional 12,600 shares during the period. Jane Street Group LLC purchased a new position in shares of Immuneering during the 1st quarter valued at $32,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Immuneering during the 3rd quarter valued at $35,000. Finally, Sanofi bought a new position in shares of Immuneering in the third quarter worth $18,960,000. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.